Patent ID: 7727967

Claim:
A pharmaceutical composition for reducing cardiotoxicity during anthracycline cancer treatment, the composition comprising at least one anthracycline compound selected from the group consisting of adriamycin, daunomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, and mixtures of two or more thereof, and at least one compound adapted to limit formation of anthracycline alcohol metabolite(s) and being a human carbonyl reductase enzyme inhibitor selected from the group consisting of: oximino(2,4-difluorophenyl)acetonitrile (“C1”), oximino(2,6-difluorophenyl)acetonitrile (“C2”), oximino(2,5-difluorophenyl)acetonitrile (“C3”), oximino(2-chloro-6-fluorophenyl)acetonitrile (“C4”), oximino(2,4-dichlorophenyl)acetonitrile (“C5”), oximino(2,6-dichlorophenyl)acetonitrile (“C6), and mixtures of two or more thereof, wherein the pharmaceutical composition comprises an amount of said anthracycline compound effective for cancer cell cytotoxicity, and the pharmaceutical composition comprises an amount of human carbonyl reductase enzyme inhibitor such that the concentration gives a K ii value in the range of 10.8-72 μM.